PT-141 vs Kisspeptin-10
Melanocortin versus kisspeptin signaling. Both act centrally on reproductive pathways through unrelated receptor systems.
Specialty
PT-141
Cyclic heptapeptide melanocortin receptor agonist, a metabolite of melanotan II studied for central MC4R signaling.
Specialty
Kisspeptin-10
C-terminal decapeptide of kisspeptin, the upstream regulator of GnRH release via the KISS1R receptor.
Side by side
| Dimension | PT-141 | Kisspeptin-10 |
|---|---|---|
| Molecular weight | 1025.16 g/mol | 1302.45 g/mol |
| Size class | short peptide | short peptide |
| CAS number | 189691-06-3 | 374675-21-5 |
| Research area | specialty | specialty |
| Sequence | Not published as a linear sequence | Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 |
| Available sizes | 10mg | 5mg |
| Entry price | $44 | $39 |
| Cost per mg | $4.40 | $7.80 |
Mechanism
PT-141
PT-141 is a cyclic heptapeptide and the deaminated metabolite of melanotan II, acting as an agonist at melanocortin receptors with principal research interest at MC4R. Unlike melanotan II it lacks significant MC1R-mediated pigmentation activity, making it a cleaner tool for isolating MC4R-mediated central effects. Its mechanism is centrally mediated rather than vascular, which distinguishes it from PDE5-targeting compounds.
Kisspeptin-10
Kisspeptin-10 is the shortest fully active fragment of kisspeptin, the product of the KISS1 gene. Its discovery reframed reproductive neuroendocrinology: kisspeptin signaling through KISS1R (GPR54) sits upstream of GnRH neurons and is now understood as a gatekeeper of the reproductive axis. Loss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism, which is the genetic evidence anchoring the pathway.
Evidence quality
Mechanism is not the same as evidence. Where we have assessed the literature, the verdict is stated plainly.
PT-141
Evidence base: strong by the standards of this catalogue. Randomised phase 3 trials, a published pooled safety analysis, and regulatory approval for a defined indication. The evidence supports the studied endpoint and population, not a general claim.
Full research reference →Kisspeptin-10
Evidence base: solid receptor pharmacology with an established genetic basis. The desensitisation result under continuous exposure is specific, published, and frequently overlooked. Non-reproductive mechanisms are emerging and less replicated.
Full research reference →Research applications
PT-141
- MC4R and MC3R binding and selectivity assays
- Central melanocortin pathway signaling studies
- Comparative receptor profiling against melanotan II
Kisspeptin-10
- KISS1R (GPR54) receptor binding and activation assays
- GnRH pulse generation studies in hypothalamic models
- Reproductive axis and puberty-onset research
- Metastasis suppression studies (the original KISS1 context)
Common questions
What is the difference between PT-141 and Kisspeptin-10?
PT-141 is cyclic heptapeptide melanocortin receptor agonist, a metabolite of melanotan II studied for central MC4R signaling. Kisspeptin-10 is c-terminal decapeptide of kisspeptin, the upstream regulator of GnRH release via the KISS1R receptor. They differ in molecular weight (1025.16 vs 1302.45 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, PT-141 or Kisspeptin-10?
PT-141 is lower at approximately $4.40 per milligram at its best tier, against $7.80 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can PT-141 and Kisspeptin-10 be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should PT-141 and Kisspeptin-10 be stored?
Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days. For Kisspeptin-10: Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days.
Which has the stronger evidence base?
PT-141 — Evidence base: strong by the standards of this catalogue. Randomised phase 3 trials, a published pooled safety analysis, and regulatory approval for a defined indication. The evidence supports the studied endpoint and population, not a general claim. Kisspeptin-10 — Evidence base: solid receptor pharmacology with an established genetic basis. The desensitisation result under continuous exposure is specific, published, and frequently overlooked. Non-reproductive mechanisms are emerging and less replicated.
All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.
Comparison generated from Lyra Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.